This Article Full Text Full Text (PDF) All Versions of this Article: 47/1/6    most recent 01.HYP.0000196685.91424.01v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raizada, M. K. Articles by Sarkissian, S. D. Search for Related Content PubMed PubMed Citation Articles by Raizada, M. K. Articles by Sarkissian, S. D. Related Collections ACE/Angiotension receptors Other hypertension Functional genomics Heart failure - basic studies Gene therapy

(Hypertension. 2006;47:6.)
© 2006 American Heart Association, Inc.

Hypertension Highlights

Potential of Gene Therapy Strategy for the Treatment of Hypertension

From the Department of Physiology and Functional Genomics, University of Florida, College of Medicine, Gainesville.

Correspondence to Mohan K. Raizada, University of Florida, 1600 SW Archer Rd, Rm M552, Gainesville, FL 32610. E-mail mraizada@phys.med.ufl.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Hypertension is one of the most important risk factors for cardiovascular diseases (CVDs). CVD extends across all populations and represents the leading cause of morbidity and mortality in industrialized countries. Hypertension increases the risk of peripheral arterial disease, cardiomyopathy, stroke, and renal failure. The disease affects &50 million Americans and goes undetected in at least one third of the population. In spite of the tremendous progress made by pharmacotherapy in the management and control of hypertension, there has been a steady escalation in its prevalence during the last decade. This has led many to conclude that traditional pharmacotherapy has reached an intellectual plateau and that novel and innovative approaches must be sought for the treatment, control, and possible cure of hypertension. As a result, efforts of our group and those of many others have been diverted to explore the use of gene transfer and gene therapy strategies for a long-term control of hypertension. We have argued that gene therapy offers potentially significant improvements and benefits over the use of traditional pharmacotherapy: (1) noncompliance by patients can be significantly reduced or even eliminated because of the fact that a single treatment involving gene transfer could remain effective for months or even years; (2) side effects associated with pharmacotherapy can be minimized as a result of specific targeting of a therapeutic gene in a given tissue and optimally influencing cardiovascular pathophysiology on an individual patient basis; and (3) with its potential to produce long-term beneficial outcomes in end-organ damage, the gene therapy . . . [Full Text of this Article]

This article has been cited by other articles:

				Z. Li, C. Yu, Y. Han, H. Ren, W. Shi, C. Fu, D. He, L. Huang, C. Yang, X. Wang, et al. Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2761 - H2768. [Abstract] [Full Text] [PDF]

				S. Der Sarkissian, J. L. Grobe, L. Yuan, D. R. Narielwala, G. A. Walter, M. J. Katovich, and M. K. Raizada Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology Hypertension, March 1, 2008; 51(3): 712 - 718. [Abstract] [Full Text] [PDF]

				C. Zeng, I. Armando, Y. Luo, G. M. Eisner, R. A. Felder, and P. A. Jose Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H551 - H569. [Abstract] [Full Text] [PDF]

				M. Yamazato, Y. Yamazato, C. Sun, C. Diez-Freire, and M. K. Raizada Overexpression of Angiotensin-Converting Enzyme 2 in the Rostral Ventrolateral Medulla Causes Long-Term Decrease in Blood Pressure in the Spontaneously Hypertensive Rats Hypertension, April 1, 2007; 49(4): 926 - 931. [Abstract] [Full Text] [PDF]